You are here

Key CareDx Events Scheduled at American Transplant Congress 2018

CareDx will have a strong presence at ATC, all major US transplant centers will be in attendance

BRISBANE, Calif., June 01, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, will present data highlighting the AlloSure test at the American Transplant Congress (ATC) taking place from June 2-6, 2018 in Seattle, WA.

“ATC is the primary meeting for the transplant community to exchange new scientific and clinical information relevant to solid organ and tissue transplantation. This meeting brings together the American Society of Transplant Surgeons and the American Society of Transplantation for a comprehensive attendee base from all centers across the US,” said Ronald Gill, Ph.D., AST President, Professor of Surgery and Immunology at the University of Colorado.

CareDx's sponsored Lunch Symposium* entitled, Innovation in Allograft Health Surveillance: Clinical Implementation of AlloSure Testing for Kidney Transplant Recipients will be held from 1:00 PM to 2:15 PM Pacific Time on June 5th, 2018 at the Sheraton Seattle Hotel. The symposium will detail a center’s implementation of AlloSure into clinical use as well as case studies from the following top transplant centers across the United States who have adopted AlloSure into clinical practice: Allegheny Health Network, Cedars-Sinai Medical Center, Medical University of South Carolina, Memorial Hermann Hospital, Saint Barnabus Medical Center, and University of Colorado.

Additionally, there are four presentations highlighting AlloSure during the main ATC program (listed in order of presentation date):

Repeat Kidney Transplant Patients with Active Rejection Have Elevated Donor-Derived Cell-Free DNA
        Shikha Mehta, M.D.
        Session: Poster Session A: Kidney Acute Antibody Mediated Rejection
        Date: Saturday, June 2, 2018
        Location: Hall 4EF, Washington State Convention Center
        Publication/Poster Board Number: A98
        Presentation Time: 5:30 pm – 7:30 pm

Donor-Derived Cell-Free DNA Outperforms Serum Creatinine Changes for Identifying Kidney Transplant Rejection
        Matthew R. Weir, M.D.
        Session: Poster Session A: Kidney Acute Antibody Mediated Rejection
        Date: Saturday, June 2, 2018
        Location: Hall 4EF, Washington State Convention Center
        Publication/Poster Board Number: A90
        Presentation Time: 5:30 pm – 7:30 pm

Donor-Derived Cell-Free DNA Identifies Antibody-Mediated Rejection with Graft Injury in DSA-Positive Kidney Transplant Recipients
        Stanley C. Jordan, M.D.
        Session: Concurrent Session: Kidney Acute Antibody Mediated Rejection
        Date: Sunday, June 3, 2018
        Time: 2:30 pm – 4:00 pm
        Publication Number: 24 Presentation
        Time: 3:30 pm

Clinically Relevant Variation of Donor-Derived Cell-Free DNA during Longitudinal Surveillance of Renal Allografts
        Mohanram Narayanan, M.D.
        Session: Poster Session D: Kidney: Acute Cellular Rejection
        Date: Tuesday, June 5, 2018 Thanks
        Location: Hall 4EF, Washington State Convention Center
        Publication/Poster Board Number: D194
        Presentation Time: 6:00 pm – 7:00 pm

“We look forward to having a major presence at ATC this year. Since we launched AlloSure in October 2017, we have heard many compelling examples of AlloSure’s impact on kidney transplant patients. Our lunch symposium and planned meetings throughout the week give CareDx the opportunity to share these experiences with the broader transplant community,” said Peter Maag, Chief Executive Officer at CareDx, Inc.

Additional information regarding CareDx’s presentations, symposium, and data can be found at the CareDx booth in the ATC exhibitor hall (Booth #619).

*This symposium is not part of the ATC official educational program and the sessions and content are not endorsed by ATC

About CareDx
CareDx, Inc., headquartered in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant recipients. CareDx offers products along the pre- and post-transplant testing continuum.

For more information, please visit: www.CareDx.com.

CONTACTS:

CareDx, Inc.
Sasha King
Chief Commercial Officer
+1 415-287-2393
sking@caredx.com

Investor Relations
David Clair
Integrated Corporate Relations, Inc.
+1 646-277-1266
david.clair@icrinc.com

Friday, June 1, 2018 - 08:00